E2 raises $80m to advance VTE system’s commercialisation
FDA-cleared in December 2025, E2’s Hēlo system is indicated for the non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature.
08 April 2026
08 April 2026
FDA-cleared in December 2025, E2’s Hēlo system is indicated for the non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.